BNTC 📈 Benitec Biopharma Ltd ADR - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US08205P1003
BNTC: Gene Therapy, RNA Interference, DNA Medicines
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California. Web URL: https://benitec.com
Additional Sources for BNTC Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BNTC Stock Overview
| Market Cap in USD | 215m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2015-08-18 |
BNTC Stock Ratings
| Growth 5y | -63.1% |
| Fundamental | - |
| Dividend | 0.30% |
| Rel. Strength Industry | 62257 |
| Analysts | 4.6/5 |
| Fair Price Momentum | 10.84 USD |
| Fair Price DCF | - |
BNTC Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | % |
| Annual Growth 5y | 0.00% |
| Payout Consistency | 1.0% |
BNTC Growth Ratios
| Growth Correlation 3m | 56.3% |
| Growth Correlation 12m | 91.8% |
| Growth Correlation 5y | -81.7% |
| CAGR 5y | -36.56% |
| CAGR/Mean DD 5y | -0.45 |
| Sharpe Ratio 12m | 1.84 |
| Alpha | 253.63 |
| Beta | 1.14 |
| Volatility | 93.42% |
| Current Volume | 82.7k |
| Average Volume 20d | 93.2k |
What is the price of BNTC stocks?
As of January 01, 2025, the stock is trading at USD 12.63 with a total of 82,670 shares traded.
Over the past week, the price has changed by +9.07%, over one month by +29.41%, over three months by +37.43% and over the past year by +286.01%.
As of January 01, 2025, the stock is trading at USD 12.63 with a total of 82,670 shares traded.
Over the past week, the price has changed by +9.07%, over one month by +29.41%, over three months by +37.43% and over the past year by +286.01%.
Is Benitec Biopharma Ltd ADR a good stock to buy?
No, based on ValueRay Analyses, Benitec Biopharma Ltd ADR (NASDAQ:BNTC) is currently (January 2025) a stock to sell. It has a ValueRay Growth Rating of -63.08 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BNTC as of January 2025 is 10.84. This means that BNTC is currently overvalued and has a potential downside of -14.17%.
No, based on ValueRay Analyses, Benitec Biopharma Ltd ADR (NASDAQ:BNTC) is currently (January 2025) a stock to sell. It has a ValueRay Growth Rating of -63.08 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BNTC as of January 2025 is 10.84. This means that BNTC is currently overvalued and has a potential downside of -14.17%.
Is BNTC a buy, sell or hold?
Benitec Biopharma Ltd ADR has received a consensus analysts rating of 4.60. Therefor, it is recommend to buy BNTC.
Benitec Biopharma Ltd ADR has received a consensus analysts rating of 4.60. Therefor, it is recommend to buy BNTC.
- Strong Buy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for BNTC stock price target?
According to ValueRays Forecast Model, BNTC Benitec Biopharma Ltd ADR will be worth about 12.1 in January 2026. The stock is currently trading at 12.63. This means that the stock has a potential downside of -4.2%.
According to ValueRays Forecast Model, BNTC Benitec Biopharma Ltd ADR will be worth about 12.1 in January 2026. The stock is currently trading at 12.63. This means that the stock has a potential downside of -4.2%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 24 | 90% |
| Analysts Target Price | 6 | -52.5% |
| ValueRay Target Price | 12.1 | -4.2% |